NCT07426458RecruitingPhase 4
Ventilation and Perfusion in Asthmatics
Ventilation and Perfusion in Individuals With Asthma
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 3 Feb 2026
- Start date
- 27 Apr 2026
- Primary completion date
- 30 Apr 2028
- Lead sponsor
- University of Miami
- Diseases
- Asthma
- NCT number
- NCT07426458
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From 27 Apr 2026 to the primary completion date, 30 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance
Other illness
- Current cigarette smoking or a past history of \>10 pack-year smoking
- Respiratory infection within 4 weeks of proposed study date
Other
- Current nicotine vaping
- Pregnant and breast-feeding women
- Forced Expiratory Volume in 1 Second (FEV1) \< 50%
- Use of beta-blockers
- Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.
Who the study is looking for
- Physician diagnosis of asthma
- Baseline Forced Expiratory Volume in 1 Second (FEV1) \< 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry
- Adults, 18-75 years of age
- Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Miami - Converge Miami Coordinator of this site? Confirm its status | Miami | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.